Table 3—

Absolute and relative changes in glucose and lipid metabolism from baseline to 12 weeks

PlaceboCLAt10c12 CLA
n191919
Insulin sensitivity (M) (mg · kg−1 · min−1)0.44 ± 1.02 (12)−0.05 ± 0.97 (−1)−0.55 ± 0.95 (−15)*
Plasma insulin (pmol/l)5.52 ± 23.3 (8)4.8 ± 19.2 (7)14.4 ± 23.7 (21)
Plasma glucose (mmol/l)−0.14 ± 0.24 (−2)0.01 ± 0.30 (0)0.21 ± 0.33 (4)
HbA1c (%)0.04 ± 0.11 (1)0.04 ± 0.12 (1)0.10 ± 0.16 (2)
Serum cholesterol (mmol/l)−0.01 ± 0.09 (0)−0.03 ± 0.1 (0)−0.01 ± 0.1 (0)
LDL cholesterol (mmol/l)−0.05 ± 0.4 (−1)−0.08 ± 0.5 (−2)−0.03 ± 0.5 (−1)
VLDL TG (mmol/l)−0.15 ± 0.4 (−10)−0.05 ± 0.4 (−4)0.21 ± 0.6 (11)§
HDL cholesterol (mmo/l)0.07 ± 0.1 (7)−0.02 ± 0.1 (−2)−0.04 ± 0.08 (−4)*
TG (mmol/l)−0.2 ± 0.6 (−10)−0.13 ± 0.5 (−8)0.02 ± 1.3 (1)
FFAs (mmol/l)0.022 ± 0.18 (4)0.005 ± 0.10 (1)0.040 ± 0.12 (7)
Glycerol (mmol/l)−0.004 ± 0.02 (−3)−0.003 ± 0.02 (−2)0.006 ± 0.02 (5)
Serum leptin (ng/ml)0.5 ± 3.6 (5)−1.1 ± 4.5 (−8)§−0.7 ± 2.7 (−6)
  • Data are means ± SD (%). Values for M, n = 18.

  • *

    * P < 0.01 vs. placebo;

  • P < 0.05 within the group;

  • P < 0.001 vs. placebo;

  • §

    § P < 0.01 within the group;

  • P < 0.05 vs. placebo.